

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/316,199

ATTY. DOCKET NO.: C1040.70006US00

FILING DATE: May 21, 1999

CONFIRMATION NO.: 7506

APPLICANT: McCluskie et al.

GROUP ART UNIT: 1633

EXAMINER: Quang Nguyen

1

of

5

OCT 02 2007

U.S. PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|-----------------------|----------|----------------------|-----------|---|---|
| | | Number | Kind Code | | |
| | | 6,221,882 | B1 | Macfarlane | 04-24-2001 |
| | | 6,399,630 | B1 | Macfarlane | 06-04-2002 |
| | | 6,479,504 | B1 | Macfarlane et al. | 11-12-2002 |
| | | 6,521,637 | B2 | Macfarlane | 02-18-2003 |
| | | 6,943,240 | B2 | Bauer et al. | 09-13-2005 |
| | | 6,949,520 | B1 | Hartmann et al. | 09-27-2005 |
| | | 7,001,890 | B1 | Wagner et al. | 02-21-2006 |
| | | 7,223,741 | B2 | Krieg | 05-29-2007 |
| | | 2002-0156033 | A1 | Bratzler et al. | 10-24-2002 |
| | | 2003-0232856 | A1 | Macfarlane | 12-18-2003 |
| | | 2004-0067902 | A9 | Bratzler et al. | 04-08-2004 |
| | | 2004-0198680 | A1 | Krieg | 10-07-2004 |
| | | 2004-0229835 | A1 | Krieg et al. | 11-18-2004 |
| | | 2004-0234512 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0235770 | A1 | Davis et al. | 11-25-2004 |
| | | 2004-0235774 | A1 | Bratzler et al. | 11-25-2004 |
| | | 2004-0235777 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0235778 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0266719 | A1 | McCluskie et al. | 12-30-2004 |
| | | 2005-0004061 | A1 | Krieg et al. | 01-06-2005 |
| | | 2005-0004062 | A1 | Krieg et al. | 01-06-2005 |
| | | 2005-0009774 | A1 | Krieg et al. | 01-13-2005 |
| | | 2005-0032734 | A1 | Davis et al. | 02-10-2005 |
| | | 2005-0032736 | A1 | Krieg et al. | 02-10-2005 |
| | | 2005-0037403 | A1 | Krieg et al. | 02-17-2005 |
| | | 2005-0037985 | A1 | Krieg et al. | 02-17-2005 |
| | | 2005-0043529 | A1 | Davis et al. | 02-24-2005 |
| | | 2005-0049215 | A1 | Krieg et al. | 03-03-2005 |
| | | 2005-0049216 | A1 | Krieg et al. | 03-03-2005 |
| | | 2005-0054601 | A1 | Wagner et al. | 03-10-2005 |
| | | 2005-0054602 | A1 | Krieg et al. | 03-10-2005 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | |
|--|---|----|---|-----------------------------|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 09/316,199 | ATTY. DOCKET NO.: C1040.70006US00 | |
| | | | | FILING DATE: May 21, 1999 | CONFIRMATION NO.: 7506 | |
| | | | | APPLICANT: McCluskie et al. | | |
| | | | | GROUP ART UNIT: 1633 | EXAMINER: Quang Nguyen | |
| Sheet | 2 | of | 5 | | | |

| | | | | | |
|--|--|--------------|----|-------------------|------------|
| | | 2005-0059619 | A1 | Krieg et al. | 03-17-2005 |
| | | 2005-0059625 | A1 | Krieg et al. | 03-17-2005 |
| | | 2005-0070491 | A1 | Krieg et al. | 03-31-2005 |
| | | 2005-0075302 | A1 | Hutcherson et al. | 04-07-2005 |
| | | 2005-0100983 | A1 | Bauer et al. | 05-12-2005 |
| | | 2005-0101554 | A1 | Krieg et al. | 05-12-2005 |
| | | 2005-0101557 | A1 | Krieg et al. | 05-12-2005 |
| | | 2005-0119273 | A1 | Lipford et al. | 06-02-2005 |
| | | 2005-0123523 | A1 | Krieg et al. | 06-09-2005 |
| | | 2005-0130911 | A1 | Uhlmann et al. | 06-16-2005 |
| | | 2005-0148537 | A1 | Krieg et al. | 07-07-2005 |
| | | 2005-0169888 | A1 | Hartman et al. | 08-04-2005 |
| | | 2005-0171047 | A1 | Krieg et al. | 08-04-2005 |
| | | 2005-0181422 | A1 | Bauer et al. | 08-18-2005 |
| | | 2005-0182017 | A1 | Krieg | 08-18-2005 |
| | | 2005-0197314 | A1 | Krieg et al. | 09-08-2005 |
| | | 2005-0215501 | A1 | Lipford et al. | 09-29-2005 |
| | | 2005-0233995 | A1 | Krieg et al. | 10-20-2005 |
| | | 2005-0233999 | A1 | Krieg et al. | 10-20-2005 |
| | | 2005-0239732 | A1 | Krieg et al. | 10-27-2005 |
| | | 2005-0239733 | A1 | Jurk et al. | 10-27-2005 |
| | | 2005-0239734 | A1 | Uhlmann et al. | 10-27-2005 |
| | | 2005-0239736 | A1 | Krieg et al. | 10-27-2005 |
| | | 2005-0244379 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0244380 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0245477 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0250726 | A1 | Krieg et al. | 11-10-2005 |
| | | 2005-0256073 | A1 | Lipford et al. | 11-17-2005 |
| | | 2005-0267064 | A1 | Krieg et al. | 12-01-2005 |
| | | 2005-0277604 | A1 | Krieg et al. | 12-15-2005 |
| | | 2005-0277609 | A1 | Krieg et al. | 12-15-2005 |
| | | 2006-0003955 | A1 | Krieg et al. | 01-05-2006 |
| | | 2006-0003962 | A1 | Ahluwalia et al. | 01-05-2006 |
| | | 2006-0019916 | A1 | Krieg et al. | 01-26-2006 |
| | | 2006-0019923 | A1 | Davis et al. | 01-26-2006 |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|---|----|---|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 09/316,199 | | ATTY. DOCKET NO.: C1040.70006US00 | |
| | | | | FILING DATE: May 21, 1999 | | CONFIRMATION NO.: 7506 | |
| | | | | APPLICANT: McCluskie et al. | | | |
| | | | | GROUP ART UNIT: 1633 | | EXAMINER: Quang Nguyen | |
| Sheet | 3 | of | 5 | | | | |

| | | | | | |
|--|--|--------------|----|------------------|------------|
| | | 2006-0058251 | A1 | Krieg et al. | 03-16-2006 |
| | | 2006-0089326 | A1 | Krieg et al. | 04-27-2006 |
| | | 2006-0094683 | A1 | Krieg et al. | 05-04-2006 |
| | | 2006-0140875 | A1 | Krieg et al. | 06-29-2006 |
| | | 2006-0154890 | A1 | Bratzler et al. | 07-13-2006 |
| | | 2006-0172966 | A1 | Lipford et al. | 08-03-2006 |
| | | 2006-0188913 | A1 | Krieg et al. | 08-24-2006 |
| | | 2006-0211639 | A1 | Bratzler et al. | 09-21-2006 |
| | | 2006-0211644 | A1 | Krieg et al. | 09-21-2006 |
| | | 2006-0229271 | A1 | Krieg et al. | 10-12-2006 |
| | | 2006-0241076 | A1 | Uhlmann et al. | 10-26-2006 |
| | | 2006-0246035 | A1 | Ahluwalia et al. | 11-02-2006 |
| | | 2006-0286070 | A1 | Hartmann et al. | 12-21-2006 |
| | | 2006-0287263 | A1 | Davis et al. | 12-21-2006 |
| | | 2007-0009482 | A1 | Krieg et al. | 01-11-2007 |
| | | 2007-0010470 | A1 | Krieg et al. | 01-11-2007 |
| | | 2007-0037767 | A1 | Bratzler et al. | 02-15-2007 |
| | | 2007-0065467 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0066553 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0066554 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0078104 | A1 | Krieg et al. | 04-05-2007 |
| | | 2007-0129320 | A9 | Davis et al. | 06-07-2007 |
| | | 2007-0142315 | A1 | Forsbach et al. | 06-21-2007 |
| | | 2007-0184465 | A1 | Wagner et al. | 08-09-2007 |
| | | 2007-0202128 | A1 | Krieg et al. | 08-30-2007 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|--------------------------|-------------|-------------------------|-------------|--------------|--|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | | WO | 99/56755 | A1 | University of Iowa Research Foundation | 11-11-1999 | |
| | | WO | 00/06588 | A1 | University of Iowa Research Foundation | 02-10-2000 | |
| | | WO | 00/14217 | A2 | CPG Immunopharmaceuticals GMBH | 03-16-2000 | |
| | | WO | 00/67023 | A1 | CPG Immunopharmaceuticals GMBH | 11-09-2000 | |
| | | WO | 2004/007743 | A2 | Coley Pharmaceutical GMBH | 01-22-2004 | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|---|----|---|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 09/316,199 | | ATTY. DOCKET NO.: C1040.70006US00 | |
| | | | | FILING DATE: May 21, 1999 | | CONFIRMATION NO.: 7506 | |
| | | | | APPLICANT: McCluskie et al. | | | |
| | | | | GROUP ART UNIT: 1633 | | EXAMINER: Quang Nguyen | |
| Sheet | 4 | of | 5 | | | | |

| | | | | | | | |
|--|--|----|-------------|----|---------------------------|------------|--|
| | | WO | 2004/026888 | A2 | Coley Pharmaceutical GMBH | 04-01-2004 | |
| | | WO | 2004/094671 | A2 | Coley Pharmaceutical GMBH | 11-04-2004 | |
| | | WO | 2006/080946 | A2 | Coley Pharmaceutical GMBH | 08-03-2006 | |
| | | WO | 2007/031877 | A2 | Coley Pharmaceutical GMBH | 03-22-2007 | |
| | | WO | 2007/038720 | A2 | Coley Pharmaceutical GMBH | 04-05-2007 | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|------------|---|----------------------|
| | | COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701. | |
| | | DAVIS et al., DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med. 1999 Mar;66(2):84-90. | |
| | | DE LA ROSA et al., Microbiological quality of pharmaceutical raw materials. Pharm Acta Helv. 1995 Sep;70(3):227-32. | |
| | | DIWAN et al., Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target. 2003;11(8-10):495-507. | |
| | | GAO et al., Swelling of hydroxypropyl methylcellulose matrix tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J Pharm Sci. 1996 Jul;85(7):732-40. | |
| | | GOMBOTZ et al., Protein release from alginate matrices. Adv Drug Deliv Rev. 1998 May 4;31(3):267-285. | |
| | | HORNER et al., Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998 Nov 25;190(1):77-82. | |
| | | LI et al., Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 2001 Oct 12;20(1-2):148-57. | |
| | | LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4. | |
| | | McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6. | |
| | | MUI et al., Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther. 2001 Sep;298(3):1185-92. | |
| | | MUTWIRI et al., Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004 May 31;97(1):1-17. | |
| | | OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|---|---|----|---|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 09/316,199 | ATTY. DOCKET NO.: C1040.70006US00 |
| | | | | FILING DATE: May 21, 1999 | CONFIRMATION NO.: 7506 |
| | | | | APPLICANT: McCluskie et al. | |
| | | | | GROUP ART UNIT: 1633 | EXAMINER: Quang Nguyen |
| Sheet | 5 | of | 5 | | |

| | | |
|--|--|--|
| | SCHIJNS. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000 Aug;12(4):456-63. | |
| | SEMPLE et al., Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2005 Mar;312(3):1020-6. | |
| | SHAO et al., CpG-containing oligodeoxynucleotide 1826 converts the weak uveitogenic rat interphotoreceptor retinoid-binding protein peptide 1181-1191 into a strong uveitogen. J Immunol. 2003 Nov 1;171(9):4780-5. | |
| | SUZUKI et al., Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 2004 Dec 1;64(23):8754-60. | |
| | TAFAGHODI et al., Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm. 2006 Aug 17;319(1-2):37-43. | |
| | TAM et al., Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides. Future Lipidology. 2006 Feb; 1(1): 35-46 | |
| | UGOZZOLI et al., Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology. 1998 Apr;93(4):563-71. | |
| | VON HUNOLSTEIN et al., Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int Immunol. 2000 Mar;12(3):295-303. | |
| | VON HUNOLSTEIN et al., The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine. 2001 Apr 30;19(23-24):3058-66. | |
| | WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int Immunol. 2003 Feb;15(2):223-31. | |
| | WEERATNA et al., TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine. 2005 Nov 1;23(45):5263-70. | |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.